FDA Approves Eli Lilly Breast Cancer Drug Verzenio
Eli Lilly and Co drug has recently won FDA approval for their drug abemaciclib, which will be sold under the brand name Verzenioto to treat advanced breast cancer that has progressed following prior treatment. Eli Lilly’s drug belongs to the class of drugs called CDK 4/6 inhibitors that block cancer cells’ ability to divide and proliferate.
An estimated 252,710 women will be diagnosed with breast cancer this year, and 40,610 will die of the disease, according to the National Institutes of Health. About 72 percent of patients with breast cancer have tumors that are HR-positive and HER2-negative.